Navigation Links
PharmAthene Reports First Quarter 2012 Financial Results
Date:5/8/2012

ive agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246.  For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
2. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
3. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
4. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
5. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
6. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
9. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
10. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Feb. 13 Pharmacyclics, Inc.,(Nasdaq: PCYC ) today ... 2008. The net loss for the second quarter of fiscal ... net loss of $5.9 million,or $0.23 per share, in the ... Total operating expenses were $4.9 million in the second quarter ...
... China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC ... manufacturer and distributor of high-quality, pharmaceutical grade,glucose products ... second,quarter of fiscal 2009 ended December 31, 2008. ... glucose products increased during the second quarter,compared with ...
... Creation Best Practice Findings to be released at SiriusDecisions B-to-B ... ... February 13, 2009 -- SiriusDecisions, the world,s leading source for ... announced that top executives from Hewlett-Packard Company, IBM Corporation and ...
Cached Biology Technology:Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 7Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 2Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 3Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 4Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 5Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 6Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 7Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 8Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 9Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 10Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results 11Senior Executives from HP, IBM and Omniture Headline "Leaders and Lessons Learned" Sales and Marketing Summit 2009 2Senior Executives from HP, IBM and Omniture Headline "Leaders and Lessons Learned" Sales and Marketing Summit 2009 3
(Date:7/11/2014)... creating a new professorship in tissue engineering to ... Molecular Engineering and the Marine Biological Laboratory, supported ... and Eugene Bell Foundation., The Eugene Bell Professorship ... for Molecular Engineering. That endowed chair holder also ... Eugene Bell Center for Regenerative Biology and Tissue ...
(Date:7/11/2014)... Shenzhen, July 10, 2014---A team of researchers from The ... have identified a gene of wild soybean linked to ... to grow in saline soil. This study published online ... to unveil novel genomic information for crop improvement. , ... to domestication and human selection, cultivated soybeans have less ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2BGI reports a novel gene for salt tolerance found in wild soybean 2Molecular snapshots of oxygen formation in photosynthesis 2
... of Warwick are examining a way of using bacteria ... that are difficult to create synthetically on a lab ... called prodiginines. , This group of antibiotics has ... to target and kill cancer cells. A synthetic prodiginine ...
... newly created by the University of California, Berkeley, and Lawrence ... the body's cells that can be flipped on and off ... Optical switches like these could trigger a chemical reaction, initiate ... cell - all at the flash of a light. ...
... engineers have developed a computer tool they say could ... women to use to prevent infection by the virus ... is a pressing challenge because women now account for ... said. , By applying fundamentals of physics and chemistry, ...
Cached Biology News:Light-sensitive photoswitches could restore sight to those with macular degeneration 2Light-sensitive photoswitches could restore sight to those with macular degeneration 3Study defines effective microbicide design for HIV/AIDS prevention 2Study defines effective microbicide design for HIV/AIDS prevention 3
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Pendrin (H-195)...
Biology Products: